Harnessing Antiviral Peptides as Means for SARS-CoV-2 Control

Several times during the past two decades, epidemic viral diseases created global challenges. Although many solutions have been proposed to deal with this tight spot, it is still believed that public vaccination represents most effective strategy handle it. So far, various kinds of vaccines including protein subunits, virus-like particles, inactivated, live attenuated, vectors, RNA, and DNA used in prevention COVID-19. Among categories vaccines, peptide a new hope for quick trustworthy access due development proteomics equipment. This review specifically focuses on therapies severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We consider here efficacy safety subunit synthetic peptides vaccine clinical trial phases. Furthermore, monoclonal antibodies ability suppress SARS-CoV-2, those candidates entered into trials until March 2023, were selected evaluated.